Arkema Shares Up 5.26% at Opening, Boosted by Q3 Earnings Release
Arkema announced its third-quarter 2025 results this morning. The company reported a 4.7% decrease in revenue at constant exchange rates, while its EBITDA fell by 23.8%. Facing reduced demand in the United States and Europe, the company also revised its targets for the current year, lowering its expected EBITDA to a range of 1.25 to 1.3 billion euros from a previous target of 1.3 to 1.4 billion euros.
Chemical Group's Stock Rises Amid Market Fluctuations
The chemical group's stock price increased by 5.26% this morning to 51.60 euros. This rise follows a tumultuous week, marked by a slight decline of 0.19% over seven days and a more significant correction of 13.78% over three months. Today's rebound is particularly noticeable as Arkema is recovering from an extremely difficult year, with a decline of 37.76% over the past twelve months. However, trading volume remains moderate, representing 0.08% of the capital, reflecting limited participation in the movement. The stock's progress also occurs in a context where the CAC 40 index is up by 0.19% at 7,980.08 points, highlighting that Arkema's rebound significantly outperforms the general market trend.
Technical Analysis Supports Potential Rebound
Free · Every morning
Technical market signals, before the opening bell.
Bullish and bearish momentum, analyst changes, stocks to watch — automatically computed from Euronext data.
✓ Before 9 AM every morning✓ Euronext data✓ AI-powered analysis
You're in — subscription confirmed!
Your first edition is on its way. Check your spam folder and add us to your contacts.
An error occurred.
Indicative data. No investment advice. Unsubscribe at any time.
Gratuit · chaque matin
Ne ratez plus rien sur vos actions
La tendance derrière les cours. L'essentiel des valeurs Euronext en quelques minutes.
📈les valeurs en mouvement, sur la durée
🎯les objectifs d'analystes qui évoluent
📰les actualités qui font bouger les cours
tendance · 6 séances
✓ C'est fait, vous êtes inscrit !
Votre première édition arrive bientôt. Pensez à vérifier vos spams.
Une erreur est survenue.
CAC 40 · SBF 120 · données indicatives · aucun conseil en investissement · désinscription à tout moment.
Technically, the stock finds support in the relative strength index positioned at 29, a level indicating an oversold condition that historically often precedes tactical rebounds. However, the price remains well below its 50-day moving average of 54.30 euros, indicating a general medium-term bearish trend. The MACD line, negative at -0.95, still lacks a clear buy signal, although the gap is gradually narrowing with the signal line positioned at -0.75. The stock maintains its support at 49.02 euros, providing a safety cushion before potential further pressures, while resistance is at 55.20 euros. With a beta of 0.29, Arkema shows a low correlation with broader market movements, which may attract investors seeking relative stability amid market turbulence.
Après des mois de janvier et février relativement faibles, la performance du premier trimestre a finalement été légèrement supérieure aux attentes.
Les volumes du Groupe sont stables, et la demande dans les segments clés est en hausse.
Risks mentioned
Impact potentiel de la crise au Moyen-Orient sur la demande mondiale.
Inflation des coûts des intrants résultant de la crise au Moyen-Orient.
Opportunities identified
Développement dans des marchés clés attractifs tels que les batteries et l'impression 3D.
Poursuite des efforts pour gérer strictement les coûts fixes.
The information presented in this article is provided for informational purposes only and does not constitute an investment recommendation, an incentive to buy or sell a financial asset, or investment advice. Readers are invited to conduct their own research before making any decision.
Investments in the stock market involve risks, including the risk of capital loss. Past performance of an asset or market is no guarantee of future results. Any investment decision should be made taking into account your personal financial situation, objectives and risk tolerance.